Compounds such as gambogenic acid [48], salvianolic acid B [49], and emodin [50] have emerged as potential therapeutic agents against renal fibrosis due to their ability to inhibit EZH2 activity and its associated epigenetic marker, H3K9me3. The gene discussed is EZH2; the disease is renal fibrosis.